Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Total Liabilities (2023 - 2025)

Zenas BioPharma has reported Total Liabilities over the past 3 years, most recently at $141.5 million for Q4 2025.

  • Quarterly results put Total Liabilities at $141.5 million for Q4 2025, up 146.04% from a year ago — trailing twelve months through Dec 2025 was $141.5 million (up 146.04% YoY), and the annual figure for FY2025 was $141.5 million, up 146.04%.
  • Total Liabilities for Q4 2025 was $141.5 million at Zenas BioPharma, up from $125.6 million in the prior quarter.
  • Over the last five years, Total Liabilities for ZBIO hit a ceiling of $288.8 million in Q2 2024 and a floor of $43.8 million in Q4 2023.
  • Median Total Liabilities over the past 3 years was $91.6 million (2024), compared with a mean of $125.9 million.
  • Peak annual rise in Total Liabilities hit 185.45% in 2025, while the deepest fall reached 81.49% in 2025.
  • Zenas BioPharma's Total Liabilities stood at $43.8 million in 2023, then soared by 31.26% to $57.5 million in 2024, then surged by 146.04% to $141.5 million in 2025.
  • The last three reported values for Total Liabilities were $141.5 million (Q4 2025), $125.6 million (Q3 2025), and $53.5 million (Q2 2025) per Business Quant data.